Paget Disease Treatment Market Report 2025

The paget disease treatment market size has grown steadily in recent years. It will grow from $2.12 billion in 2024 to $2.21 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth during the historic period can be attributed to the rising prevalence of Paget's disease, increased awareness and diagnosis rates, an aging population, the expansion of healthcare infrastructure, and the growing adoption of bisphosphonates.

The paget disease market size is expected to see steady growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 3.9%. The growth during the forecast period can be attributed to the rising demand for targeted therapies, increasing healthcare expenditure, a growing aging population, more clinical trials for novel therapies, and a greater focus on personalized medicine. Key trends during this period include advancements in treatment options, a shift toward biologic treatments, the development of combination therapies, the integration of digital health solutions, and progress in diagnostic technologies.

The growing number of arthritis cases and bone injuries is expected to drive the growth of the Paget disease treatment market. Arthritis is a condition that causes joint inflammation, while bone injuries can also contribute to its development. The rise in these conditions is linked to physical inactivity, which weakens muscles and joints, reducing their ability to support movement and absorb impact. This leads to an increased risk of joint degeneration, stiffness, and fractures over time. Paget disease treatment plays a crucial role in managing arthritis and bone injuries by alleviating bone pain, improving joint function, and preventing complications such as fractures and deformities caused by abnormal bone remodeling. For example, in February 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health institute, reported that in 2022, the age-adjusted prevalence of diagnosed arthritis among adults aged 18 and older was 18.9%, with women (21.5%) showing a higher incidence than men (16.1%). The prevalence of arthritis increases with age, ranging from 3.6% in individuals aged 18-34 to 53.9% in those aged 75 and older. This rise in arthritis and bone injuries is driving the demand for Paget disease treatments.

Companies in the Paget disease treatment market are focusing on developing innovative products, such as calcium regulators, to improve treatment efficacy, enhance patient outcomes, and expand their market presence. A calcium regulator is a medication or substance that helps control calcium levels in the blood and bones, maintaining balance to support various physiological functions. For example, in February 2025, Fresenius Kabi AG, a Germany-based healthcare company, introduced Calcitonin Salmon Injection, USP Synthetic, a calcium regulator designed to treat symptomatic Paget’s disease of the bone, hypercalcemia, and postmenopausal osteoporosis. This launch aims to provide a more cost-effective treatment option, strengthen their supply chain, and expand their portfolio of generic injectables. Fresenius Kabi has also invested significantly in its facilities to ensure a steady supply of essential medicines, aiming to enhance patient care and solidify its position as a leading healthcare provider.

In June 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Taro Pharmaceutical for approximately $347.73 million. This acquisition was intended to give Sun Pharma full control of Taro Pharmaceutical Industries Ltd., boosting its dermatology and specialty generics portfolio while streamlining operations and maximizing synergies. Taro Pharmaceutical Industries Ltd., an Israel-based company, specializes in generic and specialty medicines, including treatments for Paget’s disease.

Major players in the paget disease treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Fresenius Kabi AG, Zimmer Biomet Holdings Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Apotex Inc., Sumitomo Pharma Co. Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Endo International plc, Zakłady Farmaceutyczne Polpharma S.A., Abiogen Pharma S.p.A.

North America was the largest region in the paget disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paget disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the paget disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Paget's disease is a chronic bone disorder marked by abnormal bone remodeling, which leads to weakened and enlarged bones. Treatment generally includes medications to regulate bone metabolism and manage symptoms, pain relievers, and, in some cases, surgery to address severe bone deformities.

The primary treatments for Paget's disease include Actonel, Reclast, Zoledronic acid, Fosamax, Miacalcin, Aredia, Calcitonin, Zometa, and other therapies. Actonel is a brand name for risedronate, a medication used to treat and prevent osteoporosis by strengthening bones. These treatments are administered through various routes, such as oral, intravenous, and topical, and are distributed via different channels, including hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The key end users of these treatments are hospitals, clinics, and other healthcare providers.

The paget disease treatment market research report is one of a series of new reports that provides paget disease treatment market statistics, including the paget disease treatment industry global market size, regional shares, competitors with the paget disease treatment market share, detailed paget disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the paget disease treatment industry. This paget disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The paget disease treatment market consists of revenues earned by entities by providing services such as diagnosis services, orthopedic services, genetic counseling services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paget disease treatment market also includes sales of pain management medications, calcium and vitamin D supplements, bone density monitoring devices, and assistive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.